Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02630290
Other study ID # GZZD-2015008
Secondary ID
Status Completed
Phase Phase 4
First received December 3, 2015
Last updated August 10, 2016
Start date December 2015
Est. completion date June 2016

Study information

Verified date August 2016
Source Guangzhou First Municipal People’s Hospital
Contact n/a
Is FDA regulated No
Health authority China: Health and Family Planning Commission of Guangdong Province
Study type Interventional

Clinical Trial Summary

Dexmedetomidine, an alpha 2-adrenoreceptor agonist, has been found to exerts an excellent influences on the filed of perineural block. It could shorten the onset time and prolong the duration of the nerve block and improved postoperative pain. However, Dexmedetomidine-induced bradycardia or hypotension has recently attracted considerable attention because of potentially grave consequences, including sinus arrest and refractory cardiogenic shock. A low dose may help minimize cardiovascular risks associated with dexmedetomidine. However, few studies have addressed the clinical effects of low-dose dexmedetomidine as an perineural adjuvant. The present study was designed to test the hypothesis that low-dose dexmedetomidine added to ropivacaine would safely enhance the duration of analgesia without adverse effects when compared with ropivacaine alone. Investigators will conduct a single-center, prospective, randomized, triple-blind, controlled trial in patients undergoing elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block using either ropivacaine or ropivacaine plus low-dose dexmedetomidine. The primary outcome is self-reported duration of analgesia . Secondary outcomes include onset time and duration of motor and sensory block, total postoperative analgesics, and safety assessment (adverse effects and postoperative abnormal sensation).


Description:

Dexmedetomidine, an alpha 2-adrenoreceptor agonist, has been found to exerts an excellent influences on the filed of perineural block. It could shorten the onset time and prolong the duration of the nerve block and improved postoperative pain. However, Dexmedetomidine-induced bradycardia or hypotension has recently attracted considerable attention because of potentially grave consequences, including sinus arrest and refractory cardiogenic shock. Although meta-analysis showed that perineural dexmedetomidine as a local anaesthetic adjuvant for neuraxial and peripheral nerve blocks produced reversible bradycardia in only 7% of brachial plexus block patients and no effect on the incidence of hypotension, various clinical studies reported a significant decrease in heart rate. A low dose may help minimize cardiovascular risks associated with dexmedetomidine. However, few studies have addressed the clinical effects of low-dose dexmedetomidine as an perineural adjuvant. The present study was designed to test the hypothesis that low-dose dexmedetomidine, which till today has not been reported in the literature, added to ropivacaine for brachial plexus block would safely enhance the duration of analgesia without adverse effects when compared with ropivacaine alone. Investigators will conduct a single-center, prospective, randomized, triple-blind, controlled trial in patients undergoing elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block using either 20 mL of 0.5% ropivacaine or 0.5% ropivacaine plus 30 microg dexmedetomidine. The primary outcome is self-reported duration of analgesia . Secondary outcomes include onset time and duration of motor and sensory block, total postoperative analgesics, and safety assessment (adverse effects including cardiovascular inhibitions and postoperative abnormal sensation). Data will be collected and analyzed in a blinded fashion.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Surgery: elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block

- American Society of Anesthesiologist(ASA) physical status of ? to III

- Age between 18 to 60 years old

Exclusion Criteria:

- Having an ongoing another clinical trials

- Taking antihypertensive drugs such as methyldopa, clonidine and other a2 receptor agonist

- Peripheral neuropathy

- Cerebrovascular disease

- Psychiatric disease

- Coagulopathies

- Pregnant women

- Liver and kidney dysfunction

- Heart failure

- Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic

- Patient refusal

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Ropivacaine
Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
Ropivacaine + Dexmedetomidine
Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine

Locations

Country Name City State
China Guangzhou First Municipal People's Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangzhou First Municipal People’s Hospital

Country where clinical trial is conducted

China, 

References & Publications (4)

Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013 Jun;110(6):915-25. doi: 10.1093/bja/aet066. Epub 2013 Apr 15. Review. — View Citation

Esmaoglu A, Yegenoglu F, Akin A, Turk CY. Dexmedetomidine added to levobupivacaine prolongs axillary brachial plexus block. Anesth Analg. 2010 Dec;111(6):1548-51. doi: 10.1213/ANE.0b013e3181fa3095. Epub 2010 Oct 1. — View Citation

Marhofer D, Kettner SC, Marhofer P, Pils S, Weber M, Zeitlinger M. Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: a volunteer study. Br J Anaesth. 2013 Mar;110(3):438-42. doi: 10.1093/bja/aes400. Epub 2012 Nov 15. — View Citation

Wu HH, Wang HT, Jin JJ, Cui GB, Zhou KC, Chen Y, Chen GZ, Dong YL, Wang W. Does dexmedetomidine as a neuraxial adjuvant facilitate better anesthesia and analgesia? A systematic review and meta-analysis. PLoS One. 2014 Mar 26;9(3):e93114. doi: 10.1371/jour — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other The block performance time Time elapses from probe positioning to the end of local anesthetic injection. 1 day No
Other The number of block performance attempts Number of block performance attempts 1 day No
Primary Duration of analgesia Postoperative pain using visual analog scale (VAS, 0-100, 0 = no pain, 100 = maximum imaginable pain) will be assessed. Duration of analgesia is defined by time between administration of block and the postoperative pain >3. up to 24 hours postoperatively No
Secondary Blood pressure (BP) Noninvasive arterial BP is measured at the non-operated arm. episode of hypotension (30% decrease in mean BP in relation to baseline values) and hypertension (30% increase in mean BP in relation to baseline values) will be recorded. up to 24 hours postoperatively Yes
Secondary Heart rate (HR): HR, bradycardia (HR < 50 beats/min), and tachycardia (HR > 100 beats/min) will be recorded at the same time as BP recording. up to 24 hours postoperatively Yes
Secondary Peripheral oxygen saturation (SpO2) SpO2 and hypoxemia (SpO2 <90%) will be recorded at the same time as BP recording. up to 24 hours postoperatively Yes
Secondary Sensory block of median nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the median nerve locations. up to 30 minutes after administration of block No
Secondary Sensory block of ulnar nerve Sensory block of ulnar nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the ulnar nerve locations. up to 30 minutes after administration of block No
Secondary Sensory block of radial nerve Sensory block of radial nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the radial nerve locations. up to 30 minutes after administration of block No
Secondary Sensory block of musculocutaneous nerve Sensory block of musculocutaneous nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the musculocutaneous nerve locations. up to 30 minutes after administration of block No
Secondary Motor block of median nerve Motor block of median nerve is defined by thumb and fifth finger pinch. up to 30 minutes after administration of block No
Secondary Motor block of ulnar nerve Motor block of ulnar nerve is defined thumb and second finger pinch. up to 30 minutes after administration of block No
Secondary Motor block of radial nerve Motor block of radial nerve is defined by finger abduction. up to 30 minutes after administration of block No
Secondary Motor block of musculocutaneous nerve Motor block of musculocutaneous nerve is defined by flexion of the elbow. up to 30 minutes after administration of block No
Secondary Duration of motor block Duration of motor block is defined as the time interval between the administration of the block and the recovery of complete motor function of the hand and forearm assessed. up to 24 hours postoperatively Yes
Secondary Success rate of nerve block A successful block is defined as surgery without patient discomfort and the need for supplementation of local infiltration or general anesthesia 30 minutes after administration of block Yes
Secondary Postoperative analgesic requirement IV tramadol 50mg will be administered when postoperative pain >3, and be titrated up by 50 mg increments as needed for pain every 4 to 6 hours, with the maximum total dose of 250mg. up to 24 hours postoperatively No
Secondary Postoperative nausea and vomiting (PONV) The incidence of PONV will be recorded using a 4-point objective score (1 = no PONV;2 = mild nausea, no vomiting; 3 = excessive nausea or vomiting;4 = vomiting =2 times). up to 24 hours postoperatively Yes
Secondary Abnormal sensation of brachial plexus Patient's self-reported abnormal sensation of the hand and forearm. Day 1 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05846399 - CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) Phase 4
Withdrawn NCT04291170 - Comparison of Upper Extremity and Lower Extremity Function and Quick DASH N/A
Not yet recruiting NCT05060900 - Hand Ligament Reconstructions With Knee Collateral Ligament Allografts N/A
Active, not recruiting NCT05280704 - Traditional Dorsal Digital Block vs Volar Subcutaneous Digital Block N/A
Not yet recruiting NCT05003596 - Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand Phase 2/Phase 3
Completed NCT04068506 - Analgesic Effects of Gabapentin and Paracetamol Phase 4
Not yet recruiting NCT03937232 - Mirrored Movement Compared to Cross-education N/A
Completed NCT04328623 - Interest of Hypnosis on Pain Management During a Guided Echo Infiltration of the Hand N/A
Recruiting NCT04895891 - 3D Personalized Modelization of the Hand Using EOS Imaging System N/A
Completed NCT01210833 - Using HandTutor With Traumatic Hand Injuries: Characterizing the System N/A
Recruiting NCT06086392 - Perineural Dexamethasone in Supraclavicular Brachial Plexus Block for Anesthesia After Pediatric Hand/Wrist Surgery Phase 4
Completed NCT05878509 - Reliability and Validity of the Tampa Scale for Kinesiophobia
Withdrawn NCT04027569 - PROMs To Improve Care- Standardized vs Patient Specific N/A
Completed NCT03345693 - Use of MoTrack Therapy in At-Home Hand Rehabilitation N/A
Completed NCT06112145 - Are Rehabilitation Results in Flexor Tendon Zone II Injuries as Bad as Feared? N/A
Completed NCT03496337 - Is AMPS a Responsive Tool for Assessing Change in ADL-abilities After Finger or Hand Surgery
Completed NCT02789852 - Evaluation of the Effectiveness of Night Orthosis in Treating Women With Symptomatic Osteoarthritis in the Interphalangeal Joint of the Dominant Hand N/A
Completed NCT02331004 - Effectiveness of an Intervention Program for Fine Motor Skills N/A
Completed NCT04486053 - Long-term Results of Pediatric Flexor Tendon Injuries
Completed NCT03458013 - Psychosocial Outcomes in Hand Therapy N/A